ABSTRACT
Background: Iron deficiency anemia (IDA) is the most common type of anemia. But the incidence of iron deficiency anemia in chronic kidney disease (CKD) has not been well established in Kaveri Delta Region, Tamilnadu, India. Hence, the present study has been undertaken to evaluate the prevalence of iron deficiency anemia in chronic kidney disease patients of Kaveri Delta Region, Tamilnadu, India. Materials and Methods: The present study enrolled 221 chronic kidney disease patients from a private nephrology outpatient clinic, Tiruchirappalli. All biochemical tests were done including serum ferritin. Patients were categorized into two groups based on ferritin levels. Group 1 (N: 87) considered as case and the group 2 (N: 134) patients considered as control. These two groups were compared each other respective with gender and age groups with all parameters. Results: Out of these patients, 87 belonged to iron deficiency anemia patients. Group 1 patients (Total Number of Patients: 87 Male: 29 Female: 58) showing significantly lower serum ferritin levels (15.04±12.48) than group 2 patients (88.98±47.39) (P<0.0001). Within group 1, females had lower ferritin levels (12.98±8.84) than males (17.11±10.78) in the age group of 31-40 years (P <0.0001). Conclusion: The prevalence of iron deficiency anemia among chronic kidney disease in Kaveri Delta Region was found to be 39%.
ABSTRACT
Secondary hyperparathyroidism is common in patients with chronic kidney disease (CKD). Currently, cinacalcet has evidently improved the management of secondary hyperparathyroidism in patients on hemodialysis. Though, to the best of our knowledge, there are no studies addressing the dose regimen of cinacalcet in CKD stage II to IV. Hence we decided to study and evaluate the efficacy of cinacalcet in the treatment of secondary hyperparathyroidism in two different dose schedules. A total of 174 patients (M: 138, F: 36), ages ranging from 23 to 87 years with CKD stage II –IV not on dialysis and intact PTH (iPTH) >150 pg/dl were enrolled in this study. The study population was divided into two groups. Group I: daily 30 mg cinacalcet hydrochloride and Group II: weekly twice 30 mg cinacalcet hydrochloride. Both groups received cinacalcet hydrochloride 30 mg with the main meal. In group I, 42 patients (48 %) stopped the drug within one month due to various side effects. During the follow up, the levels of iPTH decreased significantly in both the groups within a period of four weeks & persisted till the end of the study. No significant side effects requiring stoppage of the drug were noted in the group II study population. In conclusion, cinacalcet hydrochloride 30 mg twice weekly is a safe regimen in suppressing high PTH levels in CKD patients.